NIGHTHAWK BIOSCIENCES, INC.

(NHWK)
  Report
Delayed Nyse  -  04:00 2022-06-27 pm EDT
2.650 USD   +7.72%
06/13NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
GL
06/13NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
AQ
06/06NIGHTHAWK BIOSCIENCES : CONSENT OF INDEPENDENT ACCOUNTANTS - Form 8-K/A
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/21/2022 06/22/2022 06/23/2022 06/24/2022 06/27/2022 Date
2.55(c) 2.64(c) 2.56(c) 2.46(c) 2.65(c) Last
63 436 32 992 53 593 43 781 62 768 Volume
+3.24% +3.53% -3.03% -3.91% +7.72% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 3,18 M - -
Net income 2022 -32,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,15x
Yield 2022 -
Sales 2023 3,80 M - -
Net income 2023 -35,9 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,62x
Yield 2023 -
Capitalization 68,0 M 68,0 M -
Capi. / Sales 2022 21,4x
Capi. / Sales 2023 17,9x
Nbr of Employees 49
Free-Float 94,8%
More Financials
Company
Nighthawk Biosciences, Inc., formerly Heat Biologics, Inc., is a fully integrated biopharmaceutical company. The Company specializes in the end-to-end development and commercialization of therapies that arm the immune system against a range of diseases including cancer and infectious disease. It focuses on drug development through its integrated ecosystem of subsidiary companies, which includes Skunkworx Bio... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Ratings of NightHawk Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NIGHTHAWK BIOSCIENCES, INC.
06/13NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer..
GL
06/13NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer..
AQ
06/06NIGHTHAWK BIOSCIENCES : CONSENT OF INDEPENDENT ACCOUNTANTS - Form 8-K/A
PU
06/06NIGHTHAWK BIOSCIENCES, INC. Completion of Acquisition or Disposition of Assets, Financ..
AQ
05/16NIGHTHAWK BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
05/16NightHawk Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/16NightHawk Biosciences Provides First Quarter 2022 Business Update
GL
05/11NORTH AMERICAN MORNING BRIEFING : All Eyes on Key -2-
DJ
05/10NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PT..
GL
05/10NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PT..
AQ
05/03NIGHTHAWK BIOSCIENCES, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Y..
AQ
05/03Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Unde..
GL
05/03Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Unde..
AQ
05/03Heat Biologics, Inc. will Change its Ticker to NHWK from HTBX
CI
05/03Heat Biologics, Inc. will Change its Name to NightHawk Biosciences, Inc
CI
More news
News in other languages on NIGHTHAWK BIOSCIENCES, INC.
05/16NightHawk Biosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
05/03Heat Biologics, Inc. va changer son ticker de HTBX à NHWK
04/19Heat Biologics va changer de nom pour devenir NightHawk Biosciences et adopter un nouve..
04/19Richard Myers devient président du conseil consultatif sur les bio-menaces de NightHawk
04/18L'unité Heat Biologics prévoit une nouvelle installation de bioproduction au Kansas
More news
Analyst Recommendations on NIGHTHAWK BIOSCIENCES, INC.
More recommendations
Chart NIGHTHAWK BIOSCIENCES, INC.
Duration : Period :
NightHawk Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NIGHTHAWK BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,65 $
Average target price 12,90 $
Spread / Average Target 387%
EPS Revisions
Managers and Directors
Jeff A. Wolf Chairman, President & Chief Executive Officer
William L Ostrander Chief Financial Officer, Secretary & Controller
Matthew M. Seavey Senior Director-Research
Guillermo Arana Executive Director-Clinical Development
John James Monahan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NIGHTHAWK BIOSCIENCES, INC.-19.08%63
MERCK KGAA-27.40%75 582
KYOWA KIRIN CO. LTD.-1.44%12 291
SK BIOPHARMACEUTICALS CO., LTD.-24.07%4 429
BETTA PHARMACEUTICALS CO., LTD.-22.00%3 828
YUHAN CORPORATION-10.95%2 936